Lv31
330 积分 2022-02-18 加入
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
8小时前
已完结
Out with the old, in with the new: what changes in the 9th edition of the TNM classification for lung cancer?
2个月前
已完结
[Advances in diagnosis and treatment and whole process management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer]
4个月前
已关闭
Brigatinib activates inflammasomes: Implication for immune-related adverse events
5个月前
已完结
Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion
6个月前
已完结
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease
9个月前
已完结
Auxological outcome and time to menarche following long‐acting goserelin therapy in girls with central precocious or early puberty
10个月前
已完结
Accelerated Versus Slowly Progressive Forms of Puberty in Girls with Precocious and Early Puberty. Gonadotropin Suppressive Effect and Final Height Obtained with Two Different Analogs
10个月前
已完结
Comparison of Two Different Gnrh Analogs’ Impact on Final Height in Girls with Early Puberty: Triptorelin Acetate vs. Leuprolide Acetate
10个月前
已关闭
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
11个月前
已完结
皖公网安备34019202002308
